Enrollment Passes Midpoint In Voyager Pharmaceutical Corporation's Phase III Alzheimer's Trial Ahead Of Schedule
RALEIGH, N.C., April 10 /PRNewswire/ -- Enrollment in ALADDIN VP-AD-301, the first Phase III clinical trial investigating the safety and efficacy of VP4896 in the treatment of mild to moderate Alzheimer's disease, has passed its midpoint ahead of schedule, Voyager Pharmaceutical Corporation announced Monday. Voyager initiated enrollment in September 2005 and expects to complete enrollment of all 555 subjects before December 31, 2006.
"Our experienced clinical trial sites have demonstrated tremendous commitment to this study and have been instrumental in helping us surpass our enrollment goals to this point," said Patrick Smith, the company's president and CEO. "We are pleased with the momentum of the ALADDIN study and look forward to progressing the development of VP4896." Currently, 62 sites in the United States and Canada are enrolling subjects in the ALADDIN study.
Patients being recruited into the study are 60 years of age or older with mild to moderate Alzheimer's disease and have been taking Aricept(R), Exelon(R), Razadyne(TM) (formerly Reminyl(R)) or Cognex(R) for at least four months. Physicians, patients, or caregivers interested in the ALADDIN trial should go to www.clinicaltrials.gov and type in the search word "Aladdin" to learn more, to find the most up-to-date information about the trial, or to locate an investigator site.
About Voyager Pharmaceutical Corporation
Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager's scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager's most advanced product candidate is VP4896, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, in clinical development for mild to moderate Alzheimer's disease. VP4896 decreases the amount of luteinizing hormone (LH) released by the pituitary gland which, Voyager believes, may decrease or slow the progression of Alzheimer's disease.
Voyager was founded in 2001 and is headquartered in Raleigh, N.C. Contact Information: Patrick S. Smith, President and CEO (919) 846-4880
Voyager Pharmaceutical CorporationCONTACT: Patrick S. Smith, President and CEO of Voyager PharmaceuticalCorporation, +1-919-846-4880
Web site: http://www.voyagerpharma.com/